Cover Image

A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjects

BackgroundMefunidone is a novel synthetic compound and is better when compared to pirfenidone for the anti-fibrotic treatment of renal fibrosis in end-stage renal disease. We conducted this first-in-human, phase I clinical trial to determine the safety, tolerability, and pharmacokinetic (PK) (includ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mai Han (Author), Bishan Huo (Author), Gaoyun Hu (Author), Xin Zhang (Author), Gang Cui (Author), Wei Wu (Author), Na Mi (Author), Shixi Zhang (Author), Jiangli Jin (Author), Xing Lu (Author), Bidong Wu (Author), Chunyan Xiao (Author), Jing Wang (Author), Zheng Bian (Author), Jintong Li (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mefunidone Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Yuanyuan Han, et al.
Published: (2021)

Protective effects of mefunidone on ischemia-reperfusion injury/Folic acid-induced acute kidney injury
by: Jiajia Li, et al.
Published: (2022)

Corrigendum: Protective effects of Mefunidone on ischemia-reperfusion injury/folic acid-induced acute kidney injury
by: Jiajia Li, et al.
Published: (2023)

Pharmacokinetics, metabolite profiling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects
by: Huaye Gao, et al.
Published: (2022)

Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers
by: Xiaojie Wu, et al.
Published: (2022)

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects
by: Ma J, et al.
Published: (2023)

A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza®) in Healthy Male Subjects
by: Gang Mai, et al.
Published: (2021)

Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
by: Cheung TT, et al.
Published: (2023)

A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects
by: Qian Chen, et al.
Published: (2023)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
by: Mohammad Al‐Mahdi Al‐Karagholi, et al.
Published: (2021)

A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937
by: Paul D. Benn, et al.
Published: (2023)

A phase I, single and continuous dose administration study on the safety, tolerability, and pharmacokinetics of neorudin, a novel recombinant anticoagulant protein, in healthy subjects
by: Yubin Liu, et al.
Published: (2021)

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
by: Hong Zhang, et al.
Published: (2021)

A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers
by: Tong Lin, et al.
Published: (2021)

Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial
by: Kita T, et al.
Published: (2020)

Exploring the pharmacokinetics and tolerability of cyclooxygenase inhibitor ampiroxicam: a phase I study on single and multiple oral doses
by: Pengfei Zhao, et al.
Published: (2024)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
by: Qingmei Li, et al.
Published: (2018)

Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study
by: Kai Huang, et al.
Published: (2022)

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors
by: Jingrui Liu, et al.
Published: (2021)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
by: Desmond Y. H. Yap, et al.
Published: (2021)

Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS‐1211, a tissue‐nonspecific alkaline phosphatase inhibitor
by: Sonomi Maruyama, et al.
Published: (2022)

Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers
by: Rui Zhu, et al.
Published: (2022)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
by: Samit R. Joshi, et al.
Published: (2020)

Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
by: Chan Zou, et al.
Published: (2019)

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers
by: Min Wu, et al.
Published: (2022)

Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers
by: Liu J, et al.
Published: (2020)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
by: Liu C, et al.
Published: (2019)

Safety, tolerance, and pharmacokinetics of salvianolic acid B in healthy Chinese volunteers: A randomized, double-blind, placebo-controlled phase 1 clinical trial
by: Junlin Cheng, et al.
Published: (2023)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial
by: Yu-zhou Gui, et al.
Published: (2024)

Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial
by: Takuhiro Sonoyama, et al.
Published: (2023)

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
by: Takuji Okusaka, et al.
Published: (2023)

Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19
by: Nathan D. Pfeifer, et al.
Published: (2021)

A Phase 1 Study to Assess the Pharmacokinetics, Food Effect, Safety, and Tolerability of Sepiapterin in Healthy Japanese and Non-Japanese Participants
by: Lan Gao, et al.
Published: (2024)

Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects
by: Hongjie Qian, et al.
Published: (2023)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study
by: Xue Zhao, et al.
Published: (2023)

Asenapine pharmacokinetics and tolerability in a pediatric population
by: Dogterom P, et al.
Published: (2018)

A phase I study to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of ocular GLH8NDE in healthy male adults
by: Jihyun Jung, et al.
Published: (2022)

Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA‐8010 in healthy subjects: First‐in‐human phase I study
by: Dae Young Lee, et al.
Published: (2023)

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
by: Andrew Whittaker, et al.
Published: (2020)

A Phase 1 first‐in‐human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF‐06730512 in healthy participants
by: Chay Ngee Lim, et al.
Published: (2021)